Abilify. Buy more. Save more.

LENEXA, Kan. — CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced that a subcutaneous injection formulation of the veterinary anti-emetic medication Cerenia([R])(maropitant) from Pfizer Limited contains CyDex’s Captisol([R])-enabling technology.
On September 29, 2006, the European Medicines Agency approved both the subcutaneous injection and tablet formulations of Pfizer’s Cerenia for marketing through…

May 7, 2008 (Washington) — Children who are taking antipsychotic drugs should be regularly monitored for potentially dangerous changes in body fat and lipids (blood fat).
So says a researcher who found that kids experienced almost immediate increases in body mass index (BMI) and triglyceride levels after they started taking the drugs.
On…

Drugmaker Bristol-Myers Squibb said Thursday that it would pay $499 million to settle federal investigations into its pricing, sales and marketing practices. The tentative agreement is one of the biggest in recent years for drugmakers regarding drug marketing and pricing. It aims to settle investigations into Bristol’s marketing of schizophrenia and bipolar disorder drug Abilify for conditions the drug was not approved to treat, says Bristol spokesma…

By Jeff Swiatek, The Indianapolis Star Knight Ridder/Tribune Business News
Apr. 23–The Prozac blahs seem over for Eli Lilly and Co., which on Tuesday reported its highest sales jump since the patent on its famous antidepressant expired nearly two years ago.
Sales from January through March grew 13 percent, to $2.89 billion, over the same period a year ago, the drugmaker said Tuesday.

Most Popular
Today’s Best Part-Time J…

The U.S. Food and Drug Administration has approved Abilify (aripiprazole) as an add-on therapy for people with major depressive disorder who don’t benefit enough from antidepressant therapy alone, its makers said Tuesday.
Abilify, approved in November 2002 to treat schizophrenia, is among a class of medications called atypical antipsychotics. The latest approval followed clinical studies involving 743 patients.

Most Popular
3 Questions No Job Seeker Ev…

Bristrol-Myers Squibb (BMS) and Otsuka Pharmaceutical have jointly announced that the US Food and Drug Administration (FDA) approved an additional indication for ABILIFY (aripiprazole) Tablets and Oral Solution, atypical antipsychotics, as of March 1.
With this approval, ABILIFY is now applicable to the maintenance treatm…

Depression and mental illnesses are extremely common in the world that we live in today. In every 5 American adults, at least 1 of them is suffering from either depression or mild mental illness in any given 6 months’ period. However, a point to note…the National Institute of Mental Health reveals t…

The U.S. Food and Drug Administration has approved the Bristol-Myers Squibb antipsychotic drug Abilify (aripiprazole) for adolescents aged 13 to 17 diagnosed with schizophrenia, the company said Tuesday.

Related Results

Some developmentally disabled see benefits from arip…

The U.S. Food and Drug Administration has approved Abilify (aripiprazole) to treat manic and mixed episodes in children aged 10 to 17 with bipolar 1 disorder, makers Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Inc. said Friday.
The drug has been approved for this and other uses in adults for several years.

Most P…

TOKYO — Otsuka Pharmaceutical Co., Ltd. (OPC; Head Office: Chiyoda-ku, Tokyo, Japan; President: Tatsuo Higuchi; Phone: 81-3-3292-0021) announces the launch of an atypical antipsychotic agent, Abilify(R) (development code: OPC-14597, nonproprietary name: aripiprazole), on June 8.
Abilify is an antipsychot…